Posts by Michael L. Dougan, MD, PhD
-
Concurrent Immunosuppressive Therapy With Restart of Checkpoint Inhibitor Reduces Risk of Recurrent Immune-related Enterocolitis
A retrospective study at Massachusetts General Hospital and two other centers found cancer patients who had an immune checkpoint inhibitor restarted after an episode of immune-related enterocolitis had significantly less risk of severe recurrent enterocolitis if they concurrently received infliximab or vedolizumab.
-
Bamlanivimab–Etesevimab for Mild to Moderate COVID-19 in Patients at High Risk of Progression
Michael Dougan, MD, PhD, of the Division of Gastroenterology, was an investigator in the BLAZE-1 trial that led to the emergency authorization of bamlanivimab plus etesevimab for treatment of adolescents and adults with mild or moderate COVID-19 who are at high risk of progression to severe disease.
-
Update on the Use of Human Antibody Bamlanivimab to Treat COVID-19: Q&A with Michael Dougan, MD, PhD
In this Q&A, Michael Dougan, MD, explains the interim results of the bamlanivimab clinical trial based on his experience with the trial at Massachusetts General Hospital, what has been learned about the therapy to date and what still needs to be studied for this drug to become a standard of care to treat COVID-19.
-
Centralized Processes Facilitate Clinical Trial Enrollment During COVID-19
Massachusetts General Hospital has established a centralized scientific review committee to determine which COVID-19 trials will be conducted here; a core group of physicians works with study teams to ensure we are offering trial enrollment to as many patients as possible.
-
Use of Human Antibodies to Treat COVID-19: Q&A with Michael Dougan, MD, PhD
Massachusetts General Hospital is one of the trial sites for LY-CoV555, a neutralizing IgG1 monoclonal antibody, to treat COVID-19. In this Q&A, Michael Dougan, MD, PhD, explains what is currently known about this therapy and its potential to treat COVID-19 patients.
-
Subset of Cancer Patients with Checkpoint Inhibitor–Associated Enterocolitis Respond to Budesonide
Checkpoint inhibitor–related microscopic colitis, a subset of checkpoint inhibitor–related enterocolitis, often responds to first-line budesonide, allowing patients to remain on immunotherapy.
-
Researchers Chart the Course of Severe Checkpoint Inhibitor-related Colitis
Massachusetts General Hospital researchers have charted the course of severe checkpoint inhibitor–related colitis, including the fact that it usually develops within three months, and that half of the patients require second-line immunosuppression.
Biography
Michael L. Dougan, MD, PhD, is a physician in the Division of Gastroenterology and director of the GI Center for Cancer Complications at Massachusetts General Hospital and the Mass General Cancer Center. Dr. Dougan is also a Preclinical Education Group Leader and Associate Professor of Medicine at Harvard Medical School.
Digestive Healthcare at Mass General
The Massachusetts General Hospital Digestive Healthcare Center is a collaborative practice of gastroenterologists, endoscopists, surgeons, radiologists, pathologists, hepatologists, oncologists and radiation oncologists dedicated to the prevention, diagnosis, treatment and management of digestive diseases.